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Objectives. The purpose of this study was to investigate the
angiotensin-converting enzyme (ACE) insertion/deletion (I/D) ge-
notype and endothelial cell dysfunction or hypercoagulable state
in elderly hypertensive patients.
Background. Angiotensin-converting enzyme (ACE) insertion/
deletion (I/D) polymorphism was recently reported to be associ-
ated with various cardiovascular diseases. However, the precise
mechanism of this association remains unknown, and some
confounding factors might also affect the association. Endothelial
cell dysfunction and coagulation activation play important roles
in both the atherosclerotic process and the onset of cardiovascular
events.
Methods. We identified the ACE I/D genotype and measured the
plasma levels of markers of endothelial cell damage (von Wille-
brand factor [vWF] and thrombomodulin) and of coagulation
activation (prothrombin fragment F1 1 2 [F1 1 2]) in 318
asymptomatic elderly patients with hypertension, aged 59–93
years.
Results. The vWF level was significantly higher in those with
the DD genotype (n 5 54) than in those with the II genotype (n 5
131, p < 0.0001) or with the ID genotype (n 5 133, p < 0.0001).
The TM levels were also higher in patients with the ID genotype
(p < 0.005) and the DD genotype (p < 0.01) than in those with the
II genotype. There were no differences in F1 1 2 level among the
groups. Positive correlations of systolic blood pressure with levels
of both vWF and thrombomodulin were found predominantly in
patients with the II genotype (both p < 0.001), but no correlation
was noted in those with the DD genotype.
Conclusions. Considering the increased plasma levels of both
endothelial cell-derived markers in the hypertensive patients with
ACE DD genotype, we speculate that the ACE D allele is a risk
factor for the development of hypertensive cardiovascular disease
associated with endothelial cell damage.
(J Am Coll Cardiol 1998;32:444-50)
©1998 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) plays an important role
in vascular homeostasis. ACE acts predominantly as an ectoen-
zyme of vascular endothelial cells, and is a component of the
renin–angiotensin and kallikrein– kinin systems. Recently,
ACE insertion/deletion (I/D) polymorphism was reported to
be associated with various arterial atherothrombotic diseases
in whites and in Japanese, including myocardial infarction,
coronary artery spasm, coronary atherosclerosis, hypertrophic
and ischemic cardiomyopathy and hypertensive ischemic renal
and cerebrovascular disease (1–8). However, the precise
mechanism of this association remains unknown, and some
confounding factors might also affect the association. Recently,
it was shown that the ACE DD genotype is associated not with
the progression of coronary or carotid stenosis, but with
cardiovascular events (myocardial infarction or lacunar stroke)
(7,9,10), indicating that vascular spasm or thrombosis may be
an important factor.
Endothelial cell dysfunction and coagulation activation play
important roles in both the atherosclerotic process and the
onset of cardiovascular events. Some reports indicate that this
ACE polymorphism is associated with neither insulin resis-
tance nor abnormality of fibrinolysis (11). A recognized stan-
dard for endothelial cell dysfunction is not available, and the
relationship between the ACE I/D genotype and endothelial
cell dysfunction has not been thoroughly investigated. The
plasma levels of von Willebrand factor (vWF) and thrombo-
modulin have come to be widely used as indicators of endo-
thelial cell dysfunction and damage in vivo (12–14), because
they were reported to increase in parallel with the degree of
endothelial cell damage both in vitro and in vivo (15–17).
Plasma prothrombin fragment 112 (F112) is a sensitive
indicator of coagulation activation, which may reflect hyperco-
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agulable states (18,19). The plasma levels of these molecular
markers of endothelial cell damage and coagulation activation
are increased in patients with overt and silent cardiovascular
diseases (14).
We examined the ACE I/D polymorphism and measured
the plasma levels of vWF, thrombomodulin, and F112 in
elderly hypertensive patients without overt cardiovascular dis-
ease to study the relationship of ACE I/D polymorphism to
endothelial cell damage and coagulation activation.
Methods
Subjects. We studied 318 of 407 consecutive elderly hyper-
tensive outpatients, aged 59–93 years. Hypertension was diag-
nosed when the systolic blood pressure (BP) was $140 mm Hg
and/or the diastolic BP was $90 mm Hg (20), or when the
patients were receiving antihypertensive therapy. BP was mea-
sured in the sitting position using an automated sphygmoma-
nometer (BP103N-II, Nippon Colin, Co., Ltd., Komaki, Japan)
after the patient had rested for at least 5 min. We obtained a
detailed history regarding the duration of hypertension and
cardiovascular complications, such as stroke or coronary artery
disease (myocardial infarction and angina pectoris) from each
participant, and we also conducted a physical examination and
laboratory studies, including blood and urine tests, chest X-ray,
and resting electrocardiogram (ECG). We excluded 89 pa-
tients because of renal failure, hepatic damage (serum level
of creatinine .1.5 mg/dl, blood urea nitrogen .30 mg/dl, or
aspartate aminotransferase or alanine aminotransferase
.40 IU/liter), suspected diabetes mellitus (fasting glucose
.140 mg/dl and/or hemoglobin A1c . 6.4%) or present or
previous coronary artery disease, stroke, congestive heart
failure, atrial fibrillation or malignancy. The remaining 318
hypertensive subjects met the World Health Organization
criteria for stage I or II hypertension, and none of them had
factors in their history or routine laboratory test results that
suggested secondary hypertension. No antihypertensive ther-
apy was administered in 126 (40%) of the 318 hypertensive
patients for at least 1 month before examination. All the
remaining treated patients were asked to discontinue their
antihypertensive therapy 7 to 14 days before examination, but
70 (22%) of them were not able to do so. Eighty-five subjects
(27%) were or had been taking ACE inhibitors. We also
studied a control group of 263 healthy normotensive subjects
(42% male) who participated in an annual examination whose
mean (SD) age was 71 (8.1) years.
Dyslipidemia was diagnosed when the fasting serum cho-
lesterol, triglycerides, and high density lipoprotein (HDL)
cholesterol levels were .220 mg/dl, .150 mg/dl and/or
,35 mg/dl, respectively. Smokers were defined as current
smokers. The body mass index was calculated as weight
(kg)/height (m)2. Left ventricular hypertrophy diagnosed by
ECG (ECG-LVH) was defined as abnormally high voltages of
QRS complexes (R in V5 plus S in V1 greater than 3.5 mV)
associated either with flat T waves (less than 10% of R) or with
ST segment depression and biphasic T waves (21).
This study was approved by our institutional review com-
mittee, and informed consent was obtained from each subject
studied.
Polymerase chain reaction for detection of ACE I/D poly-
morphism. Genomic deoxyribonucleic acid (DNA) was ex-
tracted from citrated whole blood using salt/chloroform by a
modification of a previously described method (22). Enzymatic
amplification of DNA was performed by polymerase chain
reaction (PCR) using 1 mg of DNA extract and thermostable
Taq polymerase (Takara Biochemical, Kyoto, Japan) by pre-
viously described methods (5). All samples were studied inde-
pendently by one of the authors (N.K.) at the Department of
Pathology at Jichi Medical School (Tochigi, Japan). To avoid
mistyping, in the samples identified as showing DD genotype
by the above method, we conducted an insertion-specific
second amplification using the insertion-specific primer of the
oligonucleotide sequences of 59 TGG GAC CAC AGC GCC
CGC CAC TAC 39 and 59 TCG CCA GCC CTC CCA TGC
CCA TAA 39 (23) and confirmed that there was no misclassi-
fication. This confirmation was independently conducted by
one of the authors (S.N.) at the Division of Genetics, Interna-
tional Center for Medical Research, Kobe University School of
Medicine (Kobe, Japan).
Assay procedures. The plasma levels of vWF and throm-
bomodulin were determined with enzyme-linked immunosor-
bent assay (ELISA) kits (Diagnostica Stago, Asnieres, France,
and Teijin Co. Ltd., Tokyo, Japan, respectively). Fibrinogen
levels were measured with a Data-Fi one-stage clotting assay
kit (Dade, FL). F112 levels were assayed with an ELISA kit
(Behringwerke AG). For vWF assay, the value of the pooled
plasma, CTS Standard Plasma (purchased from Behringwerke
AG, Marburg, Germany), was taken as 100%.
The levels of total cholesterol, triglycerides, glucose, uric
acid and creatinine were measured by routine chemical meth-
ods. HDL cholesterol was determined by an enzymatic proce-
dure after precipitation with phosphotungstic acid. Lipopro-
tein(a) was measured with an ELISA (Biopool, Umea, Sweden).
As measured in our laboratory, the coefficient of variation
was 2.5% for the fibrinogen assay, 3.8% for the vWF assay,
4.7% for the thrombomodulin assay and 4.2% for the F112
assay.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
BP 5 blood pressure
DNA 5 deoxyribonucleic acid
ECG 5 electrocardiography
ECG-LVH 5 left ventricular hypertrophy diagnosed by ECG
ELISA 5 enzyme-linked immunosorbent assay
F112 5 prothrombin fragment 112
HDL 5 high density lipoprotein
I/D 5 insertion/deletion
PCR 5 polymerase chain reaction
vWF 5 von Willebrand factor
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Statistical analysis. Data are expressed as the mean (SD).
Allele frequencies were calculated by gene counting. After
one-way analysis of variance (ANOVA), the Scheffe´ F test was
used for the comparison between mean values of two groups
for different ACE genotypes. We also used the Kruskal–Wallis
test and Mann–Whitney tests as nonparametric tests for the
comparison between median values in two groups for different
ACE genotypes. Student t test was used to test differences
between the mean values of the two groups of untreated
hypertensive subjects and those under antihypertensive treat-
ment. The chi-square test was used to compare the prevalence
of risk factors. The differences with a p value ,0.05 were
considered significant.
Results
Angiotensin-converting enzyme genotype and clinical and
metabolic characteristics of the hypertensive patients. Of the
318 hypertensive subjects studied, 131 (41%) showed ACE
genotype II, 133 (42%) genotype ID and 54 (17%) genotype
DD, and the calculated gene frequencies were 0.62 for I allele
and 0.38 for D allele. The clinical and biochemical metabolic
characteristics of the subjects with each ACE genotype are
shown in Table 1. There were no significant differences among
the three groups in the demographic data for age, gender, body
mass index, duration of hypertension, smoking status, BP level
or lipid profile. There were also no differences among the three
groups in the proportion of patients under antihypertensive
therapy or of those who were or had been taking ACE
inhibitors.
Angiotensin-converting enzyme genotypes and levels of
markers of endothelial cell damage and coagulation activation
in hypertensive subjects. The levels of the markers of endo-
thelial cell damage (vWF and thrombomodulin) and coagula-
tion activation (F112) are shown in Table 2. The vWF level
was significantly higher in the patients with DD genotype than
in those with II genotype (p , 0.0001) or ID genotype (p ,
0.0001). The thrombomodulin levels were significantly higher
in those with ID genotype (p , 0.005) and DD genotype (p ,
0.01) than in those with II genotype. When a high level of each
parameter was defined as .1 SD above the mean, the propor-
tion of the subjects with high vWF level was significantly
greater among those with DD genotype than in those with II
genotype (p , 0.005), and high thrombomodulin levels were
more common in those with the ID genotype (p , 0.05) or the
DD genotype (p , 0.001) than in those with the II genotype.
There were no significant differences among the three geno-
type groups in fibrinogen or F112 levels.
Severity and duration of hypertension and markers of
endothelial cell damage in different ACE genotypes. There
were significant positive correlations between BP and markers
of endothelial cell damage (vWF and thrombomodulin) in the
318 hypertensive patients, as shown in Table 3. For the three
groups with different ACE genotypes, however, positive corre-
lations for these associations were found predominantly in
those with the II genotype (Fig. 1). In those with the ID
genotype, there were significant correlations of systolic BP with
levels of vWF and thrombomodulin (p , 0.01), whereas there
were no correlations of BP with any marker of endothelial cell
damage in those with the DD genotype (Fig. 1).
There was no significant relationship between the duration
of hypertension and the levels of the markers of endothelial
cell damage (vWF and thrombomodulin) for either the entire
group of 318 patients or for each of the three groups with
different ACE genotypes (Table 3).
There was no significant relationship between the BP level
or the duration of hypertension and any other metabolic or
hemostatic parameter, including fibrinogen and F112, for
either the entire group or for each of the groups with different
ACE genotypes (data not shown).
Antihypertensive therapy and markers of endothelial cell
damage in hypertensive subjects. The mean (SD) levels of
endothelial cell-derived markers in the untreated hypertensive
subjects (n 5 248) were not significantly different from those in
the subjects under antihypertensive therapy (n 5 70) (vWF:
157 [42%] vs. 147 [44%]; thrombomodulin: 28 [12%] ng/ml vs.
26 [12%] ng/ml). There were also no significant differences
between the levels of these markers in those taking ACE
inhibitor and in those taking other antihypertensive agents
(data not shown).
Antihypertensive therapy did not seem to affect any meta-
bolic or hemostatic parameter, including fibrinogen and F112,
Table 1. Clinical and Biochemical Metabolic Characteristics of the
Groups of Hypertensive Subjects With Different ACE Genotypes
ACE genotype
II
(n 5 131)
ID
(n 5 133)
DD
(n 5 54)
Age (years) 72 (7.4) 69 (7.5) 70 (6.6)
Male (%) 37 45 48
Body mass index (kg/m2) 23.6 (3.5) 24.2 (3.4) 24.4 (4.0)
Duration of hypertension
(years)
5.1 (6.1) 6.1 (6.9) 7.3 (8.8)
Dyslipidemia (%) 58 59 46
Treated (%) 11 11 15
ECG-LVH (%) 16 20 20
Smoker (%) 33 31 35
Under antihypertensive
therapy (%)
21 20 30
Systolic BP (mm Hg) 162 (24) 161 (24) 161 (22)
Diastolic BP (mm Hg) 92 (15) 93 (15) 97 (13)
Heart rate (bpm) 78 (10) 78 (15) 77 (13)
Hematocrit (%) 39 (4.2) 41 (7.0) 41 (4.1)
Creatinine (mg/dl) 0.88 (0.17) 0.94 (0.28) 0.95 (0.19)
Uric acid (mg/dl) 4.9 (1.3) 5.4 (1.9) 5.2 (1.2)
Glucose (mg/dl) 98 (17) 98 (16) 98 (15)
Total cholesterol (mg/dl) 199 (36) 201 (30) 198 (37)
HDL cholesterol (mg/dl) 45 (12) 46 (12) 47 (18)
Lipoprotein (a) (mg/dl) 25 (21) 24 (19) 21 (15)
High lipoprotein (a)
level (%)
31 32 30
The mean (SD) value or prevalence (%) is shown. High lipoprotein (a) levels
are those .30 mg/dl.
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either for the entire group or for each of the groups with
different ACE genotypes (data not shown).
Angiotensin-converting enzyme genotypes and markers of
endothelial cell damage in normotensive subjects. Of the 263
elderly normotensive subjects studied, 100 (38%) showed ACE
genotype II, 133 (51%) genotype ID and 30 (11%) genotype
DD, and the calculated gene frequencies were 0.63 for I allele
and 0.37 for D allele. Therefore, the ACE genotype distribu-
tion and gene frequency in the 263 normotensive subjects were
not significantly different from those in the 203 hypertensive
subjects. In the normotensive subjects, no significant differ-
ences among the groups with different ACE genotypes were
found in the levels of either marker of endothelial cell damage
(Table 4).
Discussion
In this study of asymptomatic elderly hypertensive patients,
we clarified that the plasma levels of endothelial cell-derived
factors (vWF and thrombomodulin) were increased in those
with the ACE DD genotype, indicating that endothelial cell
damage is potentiated in those with this genotype.
Angiotensin-converting enzyme genotype and endothelial
cell damage in hypertensive patients. von Willebrand factor is
a glycoprotein stored in endothelial cells and secreted into the
circulation (24), while thrombomodulin is a membrane glyco-
protein expressed on the surface of endothelial cells, where it
is an important cofactor in the thrombin-catalyzed activation
of protein C. Soluble thrombomodulin is also present in
Table 2. Molecular Markers of Coagulation Activation and Endothelial Cell Damage in the Groups of
Hypertensive Subjects With Different ACE Genotypes
ACE genotype
II (n 5 131) ID (n 5 133) DD (n 5 54)
Fibrinogen (mg/dl)
Mean (SD) 272 (61) 262 (56) 275 (65)
Median (25th–75th percentile) 259 (228–306) 255 (222–290) 265 (228–296)
High fibrinogen level (%)1 16 9.8 17
F112 (nmol/liter)
Mean (SD) 1.29 (0.42) 1.29 (0.41) 1.32 (0.33)
Median (25th–75th percentile) 1.24 (0.98–1.51) 1.25 (1.01–1.46) 1.28 (1.06–1.55)
High F112 level (%)1 12 14 13
vWF (%)
Mean (SD) 149 (39) 150 (44) 180 (40)*****†††
Median (25th–75th percentile) 144 (124–176) 146 (122–178) 175 (146–210)*****†††
High vWF level (%)1 15 20 35***†
Thrombomodulin (ng/ml)
Mean (SD) 25 (10) 30 (13)** 31 (15)**
Median (25th–75th percentile) 23 (17–32) 26 (20–38)*** 28 (21–40)**
High thrombomodulin level (%)1 8 19* 28****
The mean (SD) values, median (25th–75th percentile) or prevalence (%) are shown. *p , 0.05, **p , 0.01, ***p ,
0.005, ****p , 0.001, *****p , 0.0001 vs. II genotype. †p , 0.05, ††p , 0.01, †††p , 0.0001 vs. ID genotype. 1 Level
exceeding 1SD above the mean level for the marker indicated.
Table 3. Relationships Between Molecular Markers of Coagulation Activation and Endothelial Cell
Damage and Blood Pressure in the Groups of Hypertensive Subjects With Different ACE Genotypes
ACE genotype
II
(n 5 131)
ID
(n 5 133)
DD
(n 5 54)
Total
(n 5 318)
Versus vWF
Systolic BP 0.390*** 0.253* 20.082 0.243***
Diastolic BP 0.313** 0.002 20.025 0.145*
Duration of hypertension 0.219 20.055 0.128 0.100
Versus thrombomodulin
Systolic BP 0.319** 0.245* 0.083 0.225***
Diastolic BP 0.169 0.285* 0.021 0.203**
Duration of hypertension 20.032 0.029 0.041 0.011
Pearson’s correlation coefficients are shown. *p , 0.01, **p , 0.001. ***p , 0.0001.
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human plasma, probably due to proteolysis (25). Although
their release mechanisms from endothelial cells are different,
in this study both vWF and thrombomodulin showed increased
levels in the subjects with the ACE DD genotype. In addition,
because vWF is an important component in the aggregation of
platelets and their adhesion to subendothelium, increased
vWF level per se may promote atherosclerosis and thrombosis
(24). Thus, endothelial cell dysfunction or damage is probably
potentiated in elderly hypertensive patients with the ACE DD
genotype. The increased cardiovascular risk associated with
the DD genotype might be mediated through endothelial cell
damage.
Relationship between BP level and endothelial cell damage
in different ACE genotypes. Increased vWF level was reported
in hypertensive patients, especially in those with silent target
organ damage (microalbuminuria and silent cerebral infarc-
tion) (13,14). In this study, positive correlations between BP
and both markers of endothelial cell damage (vWF and
thrombomodulin) were found predominantly in those with the
II genotype, whereas neither association was significant in
those with the DD genotype. Considering that there were no
significant differences in BP among the groups with the
different ACE genotypes, higher BP might be necessary to
potentiate endothelial cell damage in those with the II geno-
Figure 1. Relationship between BP and the lev-
els of endothelial cell-derived markers in hyper-
tensive patients with ACE II genotype (left) and
with ACE DD genotype (right).
Table 4. Levels of Markers of Endothelial Cell Damage in the Groups of Normotensive Subjects With
Different ACE Genotypes
ACE genotype
II
(n 5 100)
ID
(n 5 133)
DD
(n 5 30)
Age (years) 71 (7.8) 7.0 (8.2) 74 (8.7)
Male (%) 44 41 40
Body mass index (kg/m2) 24.2 (2.9) 23.7 (3.1) 23.6 (2.9)
Smoker (%) 30 32 37
Systolic BP (mm Hg) 120 (9.8) 123 (9.1) 121 (8.4)
Diastolic BP (mm Hg) 70 (7.2) 69 (7.4) 68 (9.5)
Heart rate (bpm) 71 (14) 71 (13) 73 (15)
vWF (%)
Mean (SD) 145 (38) 146 (40) 150 (38)
Median (25th–75th percentile) 140 (111–176) 139 (117–179) 142 (126–186)
Thrombomodulin (ng/ml)
Mean (SD) 26 (12) 27 (11) 27 (17)
Median (25th–75th percentile) 23 (18–33) 25 (18–33) 20 (15–35)
The mean (SD) values, median (25th–75th percentile) or prevalence (%) are shown.
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type, while in those with the DD genotype, the ACE D allele
itself might be more important than BP level in enhancing
endothelial cell damage.
Hypertension-induced potentiation of effect of ACE geno-
type on endothelial cell damage. In the normotensive subjects,
there were no significant differences among the ACE geno-
types for the levels of the two markers of endothelial cell
damage (vWF and thrombomodulin), suggesting that the effect
of ACE D allele on endothelial cell damage is augmented by
hypertension. The presence of mild hypertension, in which
systolic BP/diastolic BP is 140/90 mm Hg or more, might be
sufficient to enhance endothelial cell damage in the hyperten-
sive patients with the DD genotype, whereas in hypertensive
patients with the II genotype, higher BP levels are necessary to
enhance endothelial cell damage.
Mechanism of relationship between ACE genotype and
endothelial cell damage. The mechanism of the relationship
between ACE D allele and endothelial cell damage remains
uncertain. Compared with homozygous individuals for the I
allele, those homozygous for the D allele show a twofold
elevation of the plasma level of ACE (26), which is involved in
the rate-limiting step for angiotensin II generation in the
arterial wall (27,28). Angiotensin II may play crucial roles in
endothelial cell damage and focal spasm involving damaged
endothelial cells of the coronary artery, since several lines of
evidence suggest that it acts as a vasoconstrictor of vascular
smooth muscle (29).
Angiotensin-converting enzyme genotype and hypercoagu-
lability in hypertensive patients. In order to assess hyperco-
agulability, we measured the plasma levels of F112. The
conversion of prothrombin to thrombin is the central event in
the coagulation of blood. This reaction takes place continu-
ously at an appropriate rate under physiological conditions in
vivo. During this process, the amino acid terminus of the
prothrombin molecule is released as the inactive F112 by
factor Xa (18). The measurement of this fragment in the
bloodstream enables us to assess not only hypercoagulability
but also hypocoagulability like the condition seen in warfarin
treatment (18,19). Thus, even low-grade hypercoagulability in
the atherosclerotic process can accurately be assessed using the
level of F112. In the present study, no differences in plasma
F112 levels among the ACE genotype groups were found.
Thus, hypercoagulability might not contribute to the cardio-
vascular risk associated with the ACE DD genotype.
ACE genotype and cardiovascular disease. We recently
clarified that the ACE D allele might be associated with
ischemic stroke in hypertensive Japanese patients (5). Among
asymptomatic elderly Japanese subjects with risk factors (hy-
pertension, dyslipidemia, cigarette smoking or elevated hemat-
ocrit), the levels of F112, vWF, thrombomodulin and lipopro-
tein(a) were higher in those with silent multiple lacunar
infarction detected by magnetic resonance imaging than in
those without any lacunae, indicating that hypercoagulability,
endothelial cell damage and high lipoprotein(a) levels contrib-
ute to lacunar stroke formation (14). In individuals with these
predisposing conditions, the ACE D allele is probably a risk
factor for cardiovascular events associated with endothelial cell
damage, but it does not seem to be associated with hyperco-
agulability and high lipoprotein(a).
Racial difference and study limitations. The ACE D allele
frequencies of Japanese hypertensive patients (D 5 0.38) and
normotensive subjects (D 5 0.37) were lower than those
reported previously for Westerners and for other Japanese
populations (D 5 0.4–0.6) (1,3,30–33). Because our study
population was elderly, there is a possibility of premature
death of patients with the DD genotype due to early-onset
cardiovascular disease. However, this possibility might be low,
because there was no difference in the D allele frequency
between younger elderly subjects aged 59 to 75 years and older
elderly subjects aged 76 years or more (data not shown).
Alternatively, the lower ACE D allele frequency may be
characteristic of our district, since our normotensive control
group consisted of healthy participants in annual health exam-
inations, who were living in the same area where the hyper-
tensive patients were living. The consistency of our results
among different racial populations and the pathological rele-
vance still need to be assessed by larger prospective association
studies or linkage-based family studies.
There was considerable overlap in the levels of endothelial
cell-derived markers among the patients with ACE II, ID and
DD genotypes. We have used the levels of endothelial cell-
derived markers to assess the state of the endothelial cells.
Although there are no gold standard methods to assess the
state of endothelial cells directly, the endothelial cell damage
in patients with DD genotype should also be confirmed by
other methods to assess the state of the endothelial cells.
Conclusions. Considering the increased plasma levels of
both endothelial cell-derived markers in the hypertensive
patients with ACE DD genotype, we conclude that the ACE D
allele is probably a risk factor for the development of hyper-
tensive cardiovascular disease associated with endothelial cell
damage. There is a possibility that advancing age and hyper-
tension might reinforce the positive relationship between the
ACE D allele and endothelial cell damage.
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